Ghent (Belgium), 13 February 2024, 6:00 a.m.; bonyf NV (Mnemonic: MLBON), the next generation oral comfort expert, is a Euronext Paris listed company and specializes in the development, production and marketing of oral, denture, orthodontic and wound care products, welcomes you to invest in its shares.
bonyf’s R&D department known for its oral healthcare innovation such as PerioTabs®, denture care innovations as Nitradine® and OlivaFix® Gold, is gearing up for their latest innovation namely OLIVAFIX ALGINATE with release scheduled in Q4/2024.
The OLIVAFIX ALGINATE formulation is the next breakthrough development achieved by the bonyf group and offers denture wearers worldwide, the first 100% healthy natural-origin ingredients denture fixative cream!
Key Advancements in bonyf’s OLIVAFIX ALGINATE denture fixative cream:
Jean-Pierre Bogaert, CEO bonyf Group, expressed anticipation for the upcoming release, stating: “Our dedicated R&D team has been working tirelessly to bring forth a denture fixative cream that not only meets the highest standards of performance but also reflects our commitment to user well-being and environmental responsibility.”
bonyf’s strengths
Incorporated in 1979, bonyf specialises in the development, production and selling of cutting-edge oral & dental care products. Through its unwavering commitment to innovation and continuous improvement, bonyf makes a real difference to people suffering from dental and oral conditions. The company has its R&D facilities in Liechtenstein (in the renown dental valley), a production plant in Switzerland and distributes its product range in 37 countries worldwide. Benefiting from seven patent protected formulations and products developed in-house, bonyf expects strong future development, driven by the fast-growing oral and dental care market.
Learn more at https://bonyf.com
bonyf
Jean-Pierre Bogaert
investor@bonyf.com